Reducing Anxiety and Stress in Primary Care Patients

NCT ID: NCT03794089

Last Updated: 2023-07-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-01

Study Completion Date

2021-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anxiety is common among primary care patients, but is undertreated. The purpose of this study is to evaluate whether a brief anxiety treatment designed for VA primary care is more effective at reducing anxiety symptoms in Veterans compared to usual care. The investigators will also examine whether Veterans like the brief treatment and whether the treatment can be feasibly delivered in primary care. Forty-eight adult Veteran primary care patients from the Syracuse VAMC who are experiencing anxiety symptoms will be recruited and randomly assigned to receive the brief anxiety treatment or usual care. The brief treatment consists of up to six 30-minute sessions with a cognitive-behavioral skills focus. The investigators will compare anxiety symptom severity between the two groups at baseline and at post-assessment 16 weeks later.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background/Rationale: Many Veteran primary care patients experience impairing symptoms of anxiety, but rates of treatment are low. Primary Care-Mental Health Integration (PC-MHI), in which mental health clinicians provide brief treatment in the primary care setting, can bridge the gap between demand for, and availability of, anxiety treatment. However, brief anxiety interventions suitable for use in the PC-MHI setting are needed. Developing an effective brief PC-MHI intervention for anxiety would address a gap in VA treatment options and facilitate high quality healthcare that improves treatment engagement, clinical outcomes, and patient experience. To ensure maximum reach, this intervention should accommodate a variety of subthreshold and diagnostic anxiety presentations, as well as comorbid depression.

Objectives: The overall goal of this research program is to develop, refine, and evaluate a brief anxiety intervention that will be acceptable to Veterans and feasible for PC-MHI providers. The primary aim of the current study is to conduct a pilot randomized controlled trial to evaluate feasibility, acceptability, potential implementation barriers and facilitators, and effectiveness of the intervention compared to usual care.

Methods: This will be a pilot hybrid type I effectiveness-implementation randomized controlled trial (N = 35). The primary goal is to evaluate feasibility, acceptability, and effectiveness of the intervention in reducing anxiety symptom severity compared to usual care. The secondary goal is to collect preliminary data on implementation barriers and facilitators that may affect future real-world uptake.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anxiety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized clinical trial with randomization to the intervention condition or control condition
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
Baseline assessment, monthly follow-up assessments, and post assessment will be conducted by research assistants who are masked to participant condition

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Brief anxiety intervention

Modular anxiety intervention designed for PC-MHI, up to six 30-minute sessions occurring approximately every 2 weeks, patients select modules of interest to them to complete, emphasis on psycho-education and cognitive-behavioral coping strategies for self-management

Group Type EXPERIMENTAL

Brief anxiety intervention

Intervention Type BEHAVIORAL

Modular anxiety intervention, tailored for Veterans, with emphasis on adaptive coping skills

Usual PC-MHI care

Appointment with PC-MHI provider at local primary care clinic, providers delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PC-MHI care

Group Type ACTIVE_COMPARATOR

Usual PC-MHI care

Intervention Type BEHAVIORAL

Anxiety treatment with mental health provider in local primary care clinic

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brief anxiety intervention

Modular anxiety intervention, tailored for Veterans, with emphasis on adaptive coping skills

Intervention Type BEHAVIORAL

Usual PC-MHI care

Anxiety treatment with mental health provider in local primary care clinic

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or older
* Veteran seen in the Syracuse VA Medical Center primary care clinic in the past year
* Screen positive for current (past 2 weeks) clinically significant anxiety symptoms (8 on Generalized Anxiety Disorder-7)

Exclusion Criteria

* Inability to communicate in English (as assessed by study staff)
* Report or demonstrate hearing impairment that would preclude telephone screening (as assessed by study staff)
* Inability to demonstrate informed consent

* defined as not being able to comprehend the study description as assessed by study staff and/or not being able to answer the comprehension of consent questions
* have a diagnosis of dementia or severe cognitive impairment (defined by primary care provider or self-report, or having a diagnosis in Problem List)
* screen positive for cognitive impairment (3 or more errors on cognitive screener)
* Have a diagnosis of obsessive-compulsive disorder (OCD) or serious mental illness (SMI) in Problem List

* i.e., psychotic disorders, bipolar disorder
* Have an encounter diagnosis of post-traumatic stress disorder (PTSD) within the past 2 years OR screen positive for PTSD (3 or more on PC-PTSD-5)
* Currently in psychotherapy/counseling for anxiety and/or depression, defined as any of the following within the past 30 days:

* attending specialty mental health sessions \[excluding a single intake session\]
* attending 2 or more Primary Care-Mental Health Integration sessions
* Being hospitalized for mental health treatment
* Report severe depressive symptoms (20 or more on Patient Health Questionnaire-9)
* At imminent risk of suicide

* defined as being identified as imminent risk based on study staff's suicide risk assessment \[verified by the PI\] and in need of intensive treatment
* e.g., hospitalization\] to ensure safety
* Started or had dosage change in psychotropic medication for anxiety or depression in the past 30 days
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

VA Office of Research and Development

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robyn L. Shepardson, PhD

Role: PRINCIPAL_INVESTIGATOR

Syracuse VA Medical Center, Syracuse, NY

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Syracuse VA Medical Center, Syracuse, NY

Syracuse, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CDX 18-006

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Novel Anxiety Treatment
NCT03790696 COMPLETED NA
BEAST: A Pilot Trial
NCT05416203 COMPLETED NA
Intervention for Anxiety After Falls
NCT01268657 COMPLETED PHASE1